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Background: Atopic diseases, for example, eczema, asthma, and hay fever, are among the most 
common chronic diseases of childhood. Knowledge on health service use among children with 
atopic disease is limited. This study aimed to investigate the total use and costs of health services 
for children with and without eczema, asthma, and hay fever in a Danish general population.
Methods: We conducted a health survey with four complete birth cohorts from the City of 
Copenhagen. Individual questionnaire data on eczema, asthma, and hay fever for children aged 
3, 6, 11, and 15 years were linked to register information on use and costs of health services 
and prescribed medication and parental education. In total 9,720 children participated (50.5%).
Results: We found increased health service use (number of additional consultations per year 
[95% confidence interval]) among children with current eczema symptoms (1.77 [1.29–2.26]), 
current asthma symptoms (2.53 [2.08–2.98]), and current hay fever symptoms (1.21 [0.74–1.67]), 
compared with children without these symptoms. We also found increased use of prescribed 
medication and most subtypes of health services. Current asthma symptoms and current eczema 
symptoms, but not current hay fever symptoms, increased the health service costs with at least 
€300 per year per child.
Conclusion: Children with eczema, asthma, and hay fever used health services and prescribed 
medication more than children without these diseases.
Keywords: asthma, atopic dermatitis, costs, hay fever, health services
Introduction
Eczema, asthma, and hay fever are among the most common chronic diseases of 
childhood. As they are all associated with atopy, that is, the propensity to develop an 
IgE-mediated immune response to environmental allergens, they are often referred to 
as the atopic diseases. Several studies have examined asthma-related health service 
use among children with asthma, comparing, for example, ethnic minority children 
vs Caucasians,1 children with suboptimal vs optimal medication regimens,2 children 
with public vs private health insurances,3 or children of single vs married parents.4 
However, total health service use among children with asthma or eczema compared 
with children without these diseases is scarcely described, and studies from countries 
with universal health care access are rare.
A French study found increased use of prescribed medication and higher costs 
of general practitioner consultations and prescribed medication among children 
with atopic eczema compared with healthy controls.5 A Canadian and a German 
study found increased likelihood of consultations with the general practitioner and 
of hospitalization among children with asthma compared with children without.6,7 
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Finally, an American study of children with the same insur-
ance found increased odds of using prescribed medication, 
outpatient hospital visits, emergency department visits, and 
hospitalization among children with asthma compared with 
children without.8 We are not aware of any studies assessing 
health service use among children with hay fever or rhinitis 
compared with children without.
Due to high-quality, national registers providing access 
to administrative data for researchers, it is possible in Den-
mark to examine health service use and costs in detail at the 
individual level.9
The aim of this study was to examine use and costs of 
health services for children with and without eczema, asthma, 
and hay fever.
Methods
study population and design
The study was based on a cross-sectional child health survey 
described in detail elsewhere,10 including all children born 
in 1994, 1998, 2003, or 2006, who were resident in the City 
of Copenhagen in September 2009. Children aged 11 or 
15 years answered questionnaires themselves, whereas the 
parents answered for children aged 3 or 6 years. We linked 
questionnaire data to administrative registers on demograph-
ics, health service use and costs, prescribed medication 
use and costs, and the primary carer’s education. Statistics 
 Denmark provided register data linked by the unique personal 
identification number, the CPr number.11 register data were 
available for all the invited children.
In total, 9,720 out of 19,241 invited children partici-
pated (50.5%), with the lowest response rate among chil-
dren aged 15 years (42.4%), followed by children aged 11 
(50.9%), 6 (51.0%), and 3 years (55.2%). Most parents 
gave written, informed consent for participation when 
returning the questionnaires. For the 1,043 questionnaires 
returned without a signature, the Danish Data Protection 
Agency gave permission to consider having followed the 
written instructions and returned the questionnaire as 
informed consent. The study was approved by the Danish 
Data Protection Agency. According to Danish legislation, 
approval from the Danish Health research Ethics Com-
mittee System is not required for studies based solely on 
questionnaires and registers.
Eczema, asthma, and hay fever
Outcome measures were eczema, asthma, and hay fever 
discerned as “known disease ever” and “current symptoms”. 
The measures were adapted from the International Study of 
Asthma and Allergies in Childhood,12 and eczema symptoms 
were defined according to the United Kingdom Working 
Party’s diagnostic criteria.13 Known disease ever was defined 
as “yes” to a single question for each disease, as were current 
asthma and hay fever symptoms. Current eczema symptoms 
were defined as “yes” to one major criterion and at least two 
of four minor criteria. The definitions are described in detail 
elsewhere.10
health service use
Denmark has a tax-funded health care system with health 
services free of charge for any person resident in Denmark 
and partial reimbursement for prescribed medication.14
Total health service use in 1 year, 2009, was calculated 
as the sum of all consultations in the primary and secondary 
health care sector. In primary health care, this included any 
consultation with a general practitioner or medical special-
ist, and also approved email and telephone consultations and 
after-hours duty doctor services. In secondary (or tertiary) 
health care, this included all outpatient hospital visits, 
emergency department visits, and hospital admissions in the 
somatic and psychiatric system.
Subtypes of health services were dichotomized as 
whether or not the child had used the service during 
2009: general practitioner, atopic disease-relevant medical 
specialist (ie, dermatologist; internal medicine special-
ist; ophthalmologist; ortho-, rhino-, and laryngologist; 
or pediatrician), and after-hours duty doctor. Outpatient 
hospital, emergency department, and hospital admissions 
were given with additional variables for atopic disease-
related visits (ICD-10 codes: l20 [atopic eczema], J45, 
J46 [asthma], J30.0-4, H10.0 [allergic rhinitis]) and 
infection-related visits (A02–A09 [gastrointestinal infec-
tions], A30-49 [other bacterial infections], A80, A81, 
A85–A89 [viral infections in central nervous system], 
B00–B09, B25–B49, B95–B99 [other infectious diseases], 
H60, H65–H68, H70–H72, H75, H92 [ear infections], 
J00–J22, J32, J35.0, J36, J40–J42, J85, J86 [respiratory 
infections], l00–l08 [skin infections], n00, n01, n30, 
n39.0 [urinary tract infections], r50, r560 [fever of other 
and unknown causes]).
Total use of prescribed medication was calculated as total 
number of collected packages of prescribed medication for 
the child during 2009. Subtypes of prescribed medication 
were dichotomized as whether or not any medication of 
the following types was collected: skin medication (ACT 
codes: D01–D04, D05AA, D06–D08), respiratory or eye 
medication (r01, r03, r05, r06, S01G), systemic  hormones 
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(H02A), and anti-infective medication (J01–J05, D06, D08, 
S01A).
Total health service costs were calculated for 2009 as 
the total individual-level costs of all health services held by 
the tax-funded health care system including primary and 
secondary (tertiary) services and total costs of any prescribed 
medication. Subtypes of costs were additionally calculated as 
costs of prescribed medication and patient share of prescribed 
medication. Total and subtypes of costs of health services 
were derived from registers where exact prices of primary 
health care, prescribed medications, and diagnosis-related 
group tariffs are recorded.15
Primary carer’s education
The primary carer’s highest attained educational level as of 
October 2009 was divided into four categories: 1) master’s 
degree or higher, 2) bachelor or academy degree, 3) voca-
tional training, and 4) primary/secondary school including 
lower secondary school and general upper secondary edu-
cation. The primary carer was defined as the mother, except 
in the cases where the father had full custody of the child.
statistical analyses
We analyzed total health service use, prescribed medica-
tion use, and costs for children with each atopic disease or 
symptom group separately compared with children without, 
and adjusted for sex, age, and the primary carer’s educational 
level. We used linear regression analyses with maximum 
likelihood estimates, 95% confidence intervals (CIs), and 
test of significance.
We analyzed each subtype of health service and pre-
scribed medication by logistic regression analyses with maxi-
mum likelihood estimation of odds ratios, 95% CIs, and test 
of significance, and with the same adjustments as mentioned.
Data were weighted for nonresponse based on register 
information on sex, age, ethnicity, health service use, parental 
civil status, parental educational level, household income, 
and type of residence in order to increase representativity.16 
The weights were computed by Statistics Denmark.17 We 
also performed analyses without weighing for nonresponse, 
and the results were essentially the same. All analyses were 
performed in SAS statistical software version 9.3 (SAS 
Institute Inc., Cary, nC, USA), using their survey procedures. 
Statistical significance was defined as P<0.05.
Results
Descriptives of the population have been published previ-
ously.10 In total, 9,720 children participated. 50.3% were 
female, and 35.3%, 25.8%, 21.3%, and 17.6% of the sample 
were 3, 6, 11, and 15 years old, respectively. The prevalence of 
current symptoms was 9.5% for eczema, 11.6% for asthma, 
and 10.9% for hay fever (Table 1).
Total health service use and costs
Children in the study had, on average, six consultations with 
the health care system and used two packages of prescribed 
medication, and these services cost ~€600 per year (Table 1). 
These figures varied slightly in different subgroups of chil-
dren. Children aged 3 years had two more annual consulta-
tions than the other age groups, while children aged 15 years 
used most prescribed medication and had the highest health 
service costs.
All atopic diseases and symptoms were associated with 
increased use of health services and prescribed medication, 
also when adjusted for sex, age, and primary carer’s educa-
tional level (Table 2). Children with current eczema symptoms 
had almost two more annual consultations of any kind, and 
children with asthma, either known disease ever or current 
symptoms, had almost three more annual consultations, 
compared with children without these diseases (Table 2). 
Known asthma ever, current asthma symptoms, and current 
eczema symptoms increased the total health service costs with 
>€300 per year, whereas children with known eczema ever, 
known hay fever ever, or current hay fever symptoms had 
the same costs as children without. However, children with 
any atopic disease or symptom had higher medication costs 
and higher patient shares of medication costs compared with 
children without (Table S1). Children with known asthma 
ever or current symptoms of two or more diseases had the 
highest medication costs of ~€100 more per year compared 
with children without and the highest patient share of ~€20 
more per year (Table S1).
subtypes of health service use
The use of different health service types among subgroups of 
children is shown in Table S2. With few exceptions, children 
with any atopic disease were more likely than children with-
out to use any subtype of health services, also when adjusted 
for age, sex, and the primary carer’s educational level. The 
odds were highest for children with two or more diseases or 
symptoms (Table 3). Children with known asthma ever or 
current asthma symptoms were twice as likely as children 
without to consult a general practitioner or after-hours duty 
doctor or to be admitted to hospital. Infection-related hospital 
admissions accounted for about half of all hospital admis-
sions (Table S2). Though all atopic diseases and symptoms 
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Table 1 Characteristics of annual health service use, prescribed medication, and total costs in various subgroups of children
Subgroups N Total health service use Prescribed medication Total costs
Unweighted Mean consultations (SEM) Mean packages (SEM) Mean € (SEM)
Total 9,720 5.79 (0.06) 1.81 (0.05) 587 (33)
sex
 Female 4,890 5.78 (0.09) 1.67 (0.05) 602 (55)
 Male 4,830 5.64 (0.09) 1.95 (0.09) 572 (35)
age (years)
 3 3,433 7.35 (0.11) 1.95 (0.05) 567 (43)
 6 2,503 5.09 (0.10) 1.54 (0.10) 513 (39)
 11 2,070 4.22 (0.11) 1.49 (0.09) 416 (25)
 15 1,714 5.45 (0.16) 2.32 (0.18) 946 (150)
Primary carer’s education
 Master 2,591 5.50 (0.11) 1.71 (0.08) 506 (61)
 Bachelor 3,173 5.75 (0.10) 1.68 (0.06) 560 (53)
 Vocational 1,777 6.02 (0.14) 2.14 (0.18) 737 (110)
 school 1,959 6.09 (0.14) 1.90 (0.10) 620 (50)
Eczema
 Known disease ever 1,583 6.91 (0.16) 2.51 (0.11) 704 (94)
 Current symptoms 927 7.56 (0.21) 2.90 (0.15) 908 (167)
asthma
 Known disease ever 697 7.80 (0.28) 4.36 (0.44) 877 (86)
 Current symptoms 1,123 8.50 (0.21) 3.65 (0.26) 1,053 (148)
hay fever
 Known disease ever 858 6.40 (0.23) 2.98 (0.22) 732 (85)
 Current symptomsa 1,059 5.88 (0.19) 2.94 (0.31) 652 (64)
Known atopic disease ever
 none 6,883 5.41 (0.06) 1.44 (0.04) 537 (39)
 One 1,904 6.54 (0.14) 2.40 (0.16) 702 (86)
 Two or more 466 7.49 (0.33) 3.86 (0.28) 803 (84)
Current symptoms of atopic disease
 none 6,918 5.28 (0.06) 1.41 (0.04) 515 (37)
 One 2,063 6.99 (0.14) 2.57 (0.12) 661 (52)
 Two or moreb 474 8.11 (0.33) 4.37 (0.57) 1,348 (315)
Notes: anot measured for children aged 3 years. bFor children aged 3 years, symptoms of up to two diseases could be reported.
Abbreviation: sEM, standard error of the mean.
increased the odds of consulting an atopic disease-relevant 
specialist, less than half of the children with eczema, asthma, 
and hay fever had seen a specialist the latest year (Table S2). 
For atopic disease-related consultations, we found too few 
cases to conduct reliable analyses. Only 80 children consulted 
an outpatient hospital, eight children visited an emergency 
department, and 45 children were admitted to the hospital 
due to an atopic disease.
subtypes of prescribed medication
The use of prescribed medication subtypes among subgroups 
of children is shown in Table S3. One out of three children 
with known eczema ever or current eczema symptoms used 
prescribed skin medication, and almost half of the children 
with known asthma ever or current asthma symptoms used 
respiratory medication. Children with current symptoms 
of eczema, asthma, or hay fever, and children with known 
asthma ever used slightly more anti-infective medication 
compared with children without (Table S3), also when 
adjusted for age, sex, and the primary carer’s educational 
level (not shown).
Discussion
We found that children with atopic diseases used health 
services and prescribed medication more than children 
without atopic diseases, both in total and for most subtypes 
of health services.
This study is the first to examine health care use in chil-
dren with hay fever and contributes new, detailed data on the 
increased health care use associated with eczema, asthma, 
and hay fever in a representative sample of Danish children 
with access to universal health care. Our findings support 
the hypothesis that childhood atopic disease increases the 
total health service use and health service costs, beyond the 
atopy-related services. Of note, there was an increased risk 
of hospital admission due to infections and increased use of 
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Table 2 annual health service use and costs among children with eczema, asthma, and hay fever compared with children without
Atopic disease Total health service use 
(consultations)
Use of prescribed medication 
(packages)
Total costs (€)
Mean difference (95% CI) Mean difference (95% CI) Mean difference (95% CI)
Eczema
 Known disease ever 1.28 (0.93–1.64) 0.86 (0.63–1.09) 174 (–22 to 370)
 Current symptoms 1.77 (1.29–2.26) 1.33 (0.97–1.70) 459 (48–871)
asthma
 Known disease ever 2.75 (2.13–3.36) 2.29 (1.74–2.84) 309 (85–533)
 Current symptoms 2.53 (2.08–2.98) 1.69 (1.36–2.01) 586 (240–932)
hay fever
 Known disease ever 1.11 (0.60–1.62) 1.08 (0.64–1.51) 110 (–126 to 346)
 Current symptomsa 1.21 (0.74–1.67) 1.13 (0.65–1.62) 77 (–142 to 297)
Known atopic disease ever
 One vs none 1.24 (0.90–1.58) 0.77 (0.54–1.00) 127 (–46 to 300)
 Two or more vs none 2.54 (1.82–3.25) 2.14 (1.63–2.65) 278 (3–552)
Current atopic symptoms of atopic disease
 One vs none 1.60 (1.28–1.93) 1.03 (0.76–1.30) 188 (46–329)
 Two or more vs noneb 3.20 (2.48–3.92) 2.40 (1.83–2.96) 897 (237–1,555)
Notes: all analyses were adjusted for sex, age, and primary carer’s educational level. reference categories: known disease ever vs children without the atopic condition ever; 
current symptoms vs no current symptoms of the atopic condition. anot measured for children aged 3 years. bFor children aged 3 years, symptoms of up to two diseases 
could be reported.
Abbreviation: CI, confidence interval.
Table 3 subtypes of annual health service use among children with eczema, asthma, and hay fever compared with children without
Atopic disease General 
practitioner
Atopic disease-
relevant  
specialist
Outpatient 
hospital
After-hours 
duty doctor
Emergency 
department
Hospital 
admission
Hospital 
admission due 
to infection
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Eczema
  Known disease 
ever
1.73 (1.43–2.10) 1.60 (1.41–1.81) 1.25 (1.05–1.48) 1.17 (1.03–1.33) 1.04 (0.89–1.22) 1.14 (0.88–1.49) 1.38 (0.93–2.04)
  Current 
symptoms
2.26 (1.7–3.00) 1.88 (1.61–2.19) 1.17 (0.95–1.44) 1.30 (1.11–1.53) 1.21 (1.00–1.47) 1.46 (1.09–1.97) 1.02 (0.66–1.58)
asthma
  Known disease 
ever
2.35 (1.77–3.13) 1.37 (1.14–1.65) 1.72 (1.38–2.14) 1.93 (1.59–2.33) 1.18 (0.95–1.48) 2.03 (1.44–2.86) 2.07 (1.23–3.48)
  Current 
symptoms
2.00 (1.54–2.60) 1.32 (1.14–1.52) 1.80 (1.51–2.15) 1.71 (1.47–1.99) 1.26 (1.06–1.50) 2.21 (1.73–2.82) 2.41 (1.72–3.37)
hay fever
  Known disease 
ever
1.44 (1.14–1.82) 1.22 (1.03–1.46) 1.26 (1.01–1.57) 1.34 (1.12–1.60) 1.13 (0.91–1.40) 1.65 (1.16–2.33) 1.76 (1.01–3.05)
  Current 
symptomsa
1.64 (1.35–2.01) 1.27 (1.08–1.50) 1.24 (1.00–1.53) 1.37 (1.15–1.64) 1.16 (0.94–1.42) 1.61 (1.11–2.35) 1.72 (0.89–3.30)
Known atopic disease ever
  One vs none 1.60 (1.34–1.91) 1.39 (1.23–1.57) 1.15 (0.98–1.36) 1.28 (1.13–1.45) 1.10 (0.94–1.28) 1.28 (1.00–1.65) 1.74 (1.22–2.48)
  Two or more  
vs none
2.68 (1.91–3.76) 1.78 (1.43–2.22) 1.71 (1.29–2.25) 1.65 (1.32–2.07) 1.14 (0.87–1.50) 1.92 (1.23–3.01) 1.62 (0.68–3.83)
Current symptoms of atopic disease
  One vs none 1.73 (1.46–2.04) 1.43 (1.27–1.61) 1.30 (1.12–1.52) 1.38 (1.22–1.55) 1.24 (1.07–1.43) 1.79 (1.42–2.26) 1.91 (1.36–2.68)
  Two or more  
vs noneb
2.97 (1.99–4.42) 1.81 (1.46–2.24) 1.89 (1.45–2.47) 2.03 (1.62–2.55) 1.26 (0.96–1.66) 2.51 (1.69–3.72) 1.99 (1.07–3.69)
Notes: all analyses were adjusted for sex, age, and primary carer’s educational level. reference categories: known disease ever vs children without the atopic condition ever; 
current symptoms vs no current symptoms of the atopic condition. anot measured for children aged 3 years. bFor children aged 3 years, symptoms of up to two diseases 
could be reported.
Abbreviations: OR, odds ratio; CI, confidence interval.
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anti-infective medication among children with atopic disease 
compared with other children, reflecting the burden of infec-
tious disease comorbidity.
Our findings are in agreement with the French study of 
children with atopic eczema5 and the Canadian, German, and 
American studies of children with asthma6–8 described in the 
“Introduction” section, and extend their findings by describ-
ing total health service use, but also more detailed subtypes 
of health services, medications, and costs. Furthermore, 
our results confirm other studies showing that far from all 
children with atopic disease get specialized treatment, even 
though it is recommended.18–20
The strengths of this study include complete data on 
detailed, individual-level register-based measures of all health 
services, costs, and educational level. Data from registries 
are generally considered reliable and without recall bias. 
Secondly, we used validated measures of atopic diseases, 
both known disease ever and current symptoms regardless 
of diagnosis, which is important when examining diseases 
expected to be underdiagnosed. Thirdly, we had a relatively 
homogenous study population in respect to accessibility of 
health services free of charge, and supply of facilities such 
as specialists and emergency departments, and with regular 
health examinations of children at different ages.
limitations include lack of objective measures of atopic 
disease such as lung function or atopic disease tests and 
of severity measures. The variable “known disease ever” 
may include some children not currently affected, and a 
proportion of the children with “current symptoms of dis-
ease” may be undiagnosed. Our definitions may thus be a 
mixture of different phenotypes with different health care 
needs. This may in part explain the relatively low propor-
tion of children  receiving specialized treatment, and affect 
our estimates toward the null. Secondly, whereas register 
data are considered reliable concerning  frequency, date, 
and duration of contacts, data from the primary health care 
sector are unspecific regarding the indication of health ser-
vices. Therefore, we could not assess atopic disease-related 
primary health care consultations. Also, in analyses of cost 
of each specific disease, there may be a contribution of cost 
from other conditions. Moreover, the registers only contain 
prescribed medication, not over-the-counter medication such 
as many skin products and hay fever products, which are 
absent in our measures of medication use and costs. Every 
third prescription had no defined daily dose, so instead we 
used packages as unit, which is less precise. Thirdly, non-
response bias is possible despite the detailed weighting for 
nonresponse. Even if a high degree of representativity is 
achieved, the results may only be applicable to children in 
the Danish health care system. Finally, we were limited by 
the cross-sectional design with no possibility to determine 
causality. We expect a circular relation, where atopic disease 
increases health service use, and at the same time, health 
service use increases the likelihood of known disease. We find 
the same tendencies when measuring known disease ever and 
current symptoms. We do, however, find a tendency toward 
lower use of health services among children with symptoms 
compared with children with known disease ever. This sug-
gests a potential for improving early and sufficient detection 
of atopic diseases in children.
Conclusion
Eczema, asthma, and hay fever increased the use of most 
health services and prescribed medication in children. 
Children with two or more atopic diseases used most health 
services and medication and had the highest costs.
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Table S1 annual medication costs and patient share of medication costs among children with eczema, asthma, or hay fever compared 
with children without
Atopic disease Medication costs (€) Patient share of medication costs (€)
Mean difference (95% CI) Mean difference (95% CI)
Eczema
 Known disease ever 19.90 (8.88–30.91) 6.93 (4.65–9.20)
 Current symptoms 33.27 (13.16–53.37) 10.80 (6.33–15.27)
asthma
 Known disease ever 92.21 (55.27–129.16) 20.35 (15.47–25.24)
 Current symptoms 55.46 (35.41–75.50) 17.90 (12.99–22.82)
hay fever
 Known disease ever 26.56 (2.05–51.06) 8.27 (4.72–11.82)
 Current symptomsa 46.43 (15.69–77.18) 9.15 (4.93–13.38)
Known atopic disease ever
 One vs none 21.91 (6.94–36.88) 5.71 (3.52–7.89)
 Two or more vs none 63.23 (39.02–87.44) 20.54 (14.79–26.29)
Current symptoms of atopic disease
 One vs none 25.99 (9.96–42.01) 6.61 (4.73–8.50)
 Two or more vs noneb 95.83 (55.31–136.35) 28.57 (18.64–38.49)
Notes: all analyses were adjusted for sex, age, and primary carer’s educational level. reference categories: known disease ever vs children without the atopic condition ever; 
current symptoms vs no current symptoms of the atopic condition. anot measured for children aged 3 years. bFor children aged 3 years, symptoms of up to two diseases 
could be reported.
Abbreviation: CI, confidence interval.
Table S2 annual use of different types of health services among various subgroups of children
Atopic disease General 
practitioner
General 
practitioner
Atopic disease-
relevant 
specialist
Outpatient 
hospital
After-hours 
duty doctor
Emergency 
department
Hospital 
admission
Hospital 
admission 
due to 
infection
Mean (SD) % % % % % % %
Total 3.45 (3.36) 83.8 28.8 13.8 36.7 16.8 5.2 2.2
sex
 Female 3.51 (3.50) 83.1 26.3 12.5 36.7 15.6 4.7 2.2
 Male 3.22 (3.33) 81.0 27.1 15.4 36.6 20.6 5.9 2.1
age (years)
 3 4.39 (3.60) 92.3 29.7 13.4 54.9 19.1 7.3 3.6
 6 2.95 (2.93) 81.2 27.6 13.1 38.2 14.1 4.9 2.2
 11 2.32 (2.79) 70.4 24.7 13.7 22.7 19.1 3.7 0.9
 15 3.34 (3.79) 79.1 23.1 16.3 21.0 20.6 4.5 0.9
Eczema
  Known disease 
ever
4.06 (3.53) 89.3 37.4 15.5 40.7 17.7 5.9 2.8
  Current 
symptoms
4.47 (3.76) 92.6 41.5 15.3 43.7 19.3 7.1 2.8
asthma
  Known disease 
ever
4.52 (4.16) 89.8 35.0 21.5 40.2 19.1 8.0 3.3
  Current 
symptoms
4.95 (3.96) 92.3 36.6 20.7 49.1 20.2 10.4 5.3
hay fever
  Known disease 
ever
3.70 (3.66) 85.1 32.8 17.5 32.9 18.4 6.5 2.2
  Current 
symptomsa
3.48 (3.62) 82.5 31.6 16.4 27.0 17.3 4.8 1.6
(Continued)
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Table S2 (Continued)
Atopic disease General 
practitioner
General 
practitioner
Atopic disease-
relevant 
specialist
Outpatient 
hospital
After-hours 
duty doctor
Emergency 
department
Hospital 
admission
Hospital 
admission 
due to 
infection
Mean (SD) % % % % % % %
Known atopic disease ever
 none 3.24 (3.19) 82.3 26.7 12.7 36.2 16.3 4.8 1.9
 One 3.87 (3.66) 87.3 33.6 15.4 38.5 17.7 5.9 3.2
 Two or more 4.32 (3.70) 89.9 39.1 20.0 37.1 19.1 6.9 1.7
Current symptoms of atopic disease
 none 3.16 (3.14) 82.2 26.6 12.6 35.5 15.9 4.3 1.7
 One 4.14 (3.73) 88.0 34.1 15.9 40.3 19.0 7.2 3.5
 Two or moreb 4.69 (4.04) 91.8 41.6 21.3 40.3 18.4 8.4 3.0
Notes: anot measured for children aged 3 years. bFor children aged 3 years, symptoms of up to two diseases could be reported.
Abbreviation: sD, standard deviation.
Table S3 Use of skin medication, respiratory medication, and anti-infective medication in 2009 among various subgroups of children
Subgroup Skin medication
%
Respiratory medication
%
Anti-infective medication
%
Total 14.0 12.7 37.6
sex
 Female 13.6 10.9 37.6
 Male 14.4 14.5 37.5
age (years)
 3 17.8 15.1 53.5
 6 13.2 10.3 35.1
 11 10.4 11.2 22.6
 15 11.9 13.2 27.4
Eczema
 Known disease ever 27.9 20.3 40.1
 Current symptoms 38.5 20.5 43.0
asthma
 Known disease ever 17.6 46.2 39.3
 Current symptoms 18.3 42.0 47.6
hay fever
 Known disease ever 17.8 33.3 33.3
 Current symptomsa 15.5 24.6 30.2
Known atopic disease ever
 none 11.2 8.0 37.1
 One 21.3 19.1 39.9
 Two or more 25.3 45.7 35.2
Current symptoms of atopic disease
 none 11.2 7.5 36.6
 One 20.3 23.7 40.7
 Two or moreb 29.5 41.1 39.9
Notes: anot measured for children aged 3 years. bFor children aged 3 years, symptoms of up to two diseases could be reported.
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